ALPHAMAB ONCOLO.DL-000002 (3NK) - Total Liabilities
Based on the latest financial reports, ALPHAMAB ONCOLO.DL-000002 (3NK) has total liabilities worth €386.17 Million EUR (≈ $451.47 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of ALPHAMAB ONCOLO.DL-000002 to track the company's year-over-year net asset growth rate.
ALPHAMAB ONCOLO.DL-000002 - Total Liabilities Trend (2021–2025)
This chart illustrates how ALPHAMAB ONCOLO.DL-000002's total liabilities have evolved over time, based on quarterly financial data. See ALPHAMAB ONCOLO.DL-000002 (3NK) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
ALPHAMAB ONCOLO.DL-000002 Competitors by Total Liabilities
The table below lists competitors of ALPHAMAB ONCOLO.DL-000002 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Olema Pharmaceuticals Inc
NASDAQ:OLMA
|
USA | $50.17 Million |
|
Plazza AG
SW:PLAN
|
Switzerland | CHF498.87 Million |
|
Troax Group AB
ST:TROAX
|
Sweden | Skr250.50 Million |
|
Nanjing Red Sun Co Ltd
SHE:000525
|
China | CN¥4.14 Billion |
|
Trican Well Service Ltd.
TO:TCW
|
Canada | CA$317.87 Million |
|
Suzhou Shijia Science & Technology Inc
SHE:002796
|
China | CN¥629.19 Million |
|
Jiangsu Sanfangxiang Industry Co Ltd
SHG:600370
|
China | CN¥12.02 Billion |
|
Tortoise Energy Infrastructure Closed Fund
NYSE:TYG
|
USA | $304.75 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down ALPHAMAB ONCOLO.DL-000002's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 3NK market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ALPHAMAB ONCOLO.DL-000002's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ALPHAMAB ONCOLO.DL-000002 (2021–2025)
The table below shows the annual total liabilities of ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €386.17 Million ≈ $451.47 Million |
-5.78% |
| 2024-12-31 | €409.87 Million ≈ $479.18 Million |
-11.86% |
| 2023-12-31 | €465.00 Million ≈ $543.64 Million |
-16.94% |
| 2022-12-31 | €559.86 Million ≈ $654.53 Million |
-32.94% |
| 2021-12-31 | €834.80 Million ≈ $975.97 Million |
-- |
About ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors… Read more